Table 3.
HNC cell drug resistance-related lncRNAs
| Tumor type | lncRNA | Cell line | Expression level | Target | Functions | Corresponding drugs | Ref. |
| NPC | TINCR | NP69 N2Tert CNE-1, HK-1 | Up | ACLY | Activate TINCR-ACLY-PADI1-MAPK-MMP2/9 axis | CDDP | [111] |
| NPC | NEAT1 | C666-1, CNE-1, CNE-2 | Up | miR-129 | Modulate the miR-129/Bcl-2 axis | HDACis | [112] |
| HNSCC | HOTAI | SCC25, Cal27, UM1 | Up | EZH2 | Promote the growth of HNSCC cells. | CDDP/cetuximab | [116] |
| HNSCC | POP1-1 | HN4, HN30 | Up | MCM5 | Facilitate the repair of DNA damage | CDDP | [117] |
| LSCC | FOXD2-AS1 | Hep2, TU-212 | Up | STAT3 | Promote STAT3 transcriptional activity | CDDP | [119] |
| OSCC | CYTOR | CAL-27, SCC4 | Up | ceRNA | Activate CYTOR/LPP axis | CDDP | [76] |
| OSCC | HOXA11-AS | HSC3, HSC4 | Up | microRNA-494 | Facilitate tumor growth | Dicoumarol | [56] |
| OSCC | EGFR-AS1 | primary cell cultures | Up | / | Resistance to EGFR TKIs | TKIs | [126] |
| PTC | GLTC | BCPAP, TPC-1, KTC-1 | Up | LDHA | Resistance to RAI | RAI | [123] |
HNC: Head and neck cancer; NPC: nasopharyngeal carcinoma; CDDP: cisplatin; HNSCC: head and neck squamous cell carcinoma; LSCC: laryngeal squamous cell carcinoma; OSCC: oral squamous cell carcinoma; EGFR: epidermal growth factor receptor; TKIs: tyrosine kinase inhibitors; PTC: papillary thyroid cancer; GLTC: glycolysis-associated regulator of LDHA post-transcriptional modification; LDHA: lactate dehydrogenase A; RAI: radioiodine.